LUA005

LUA005 is a differentiated bivalent EGFR/cMET bispecific antibody-drug conjugate (ADC) developed by Qilu Pharmaceutical. It is engineered with bivalent arms for both EGFR and cMET, employing a low-affinity but high-avidity binding strategy for EGFR and high-affinity binding for cMET. This design is intended to minimize on-target off-tumor toxicity in normal tissues, such as skin keratinocytes, while ensuring robust efficacy across heterogeneous tumors. LUA005 is built on Qilu's proprietary topoisomerase-1 inhibitor platform, featuring a hydrophilic cleavable linker and a uniform drug-to-antibody ratio (DAR) of 8. The payload is a novel topoisomerase-1 inhibitor that exhibits nanomolar activity and faster systemic clearance than Dxd, potentially improving the therapeutic window. Preclinical studies have shown superior antitumor activity in various models, including those resistant to osimertinib and cetuximab, with clinical trials expected to commence in early 2026.